---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000059"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:33.424068+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering

## Summary
- Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.
- Leerink Partners acts as sales agent, earning a commission of up to 3.0% of gross proceeds.
- Sales may be made directly on the Nasdaq Global Market; company not obligated to sell any shares.
- Original sales agreement dated May 3, 2021; shelf registration statement effective May 3, 2024.

## SEC filing metadata
- accession: 0001664710-24-000059
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/0001664710-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/kros-20240617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000059
- JSON: https://secwatch.observer/filing/0001664710-24-000059.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.